A
Aaron M. Goodman
Researcher at University of California, San Diego
Publications - 105
Citations - 5202
Aaron M. Goodman is an academic researcher from University of California, San Diego. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 21, co-authored 73 publications receiving 3041 citations. Previous affiliations of Aaron M. Goodman include University of California, Berkeley.
Papers
More filters
Journal ArticleDOI
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock +8 more
TL;DR: Higher TMB predicts favorable outcome to PD-1/PD-L1 blockade across diverse cancers treated with various immunotherapies, and Benefit from dual checkpoint blockade did not show a similarly strong dependence on TMB.
Journal ArticleDOI
Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate
Shumei Kato,Aaron M. Goodman,Vighnesh Walavalkar,Donald A. Barkauskas,Andrew B. Sharabi,Razelle Kurzrock +5 more
TL;DR: Genomic profiles may help to identify patients at risk for hyperprogression on immunotherapy, and significantly increased rate of tumor growth after single-agent checkpoint (PD-1/PD-L1) inhibitors.
Journal ArticleDOI
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
TL;DR: Tumor mutational burden reflects cancer mutation quantity, and higher TMB results in more neo-antigens, increasing chances for T cell recognition, and clinically correlates with better ICI outcomes, Nevertheless, TMB is an imperfect response biomarker.
Journal ArticleDOI
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas
TL;DR: The role of PD-1–PD-L1 blockade in unleashing host antitumour immune responses against various B-cell lymphomas is focused on, and the clinical studies of this approach performed to date are summarized.
Journal ArticleDOI
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Aaron M. Goodman,David Piccioni,Shumei Kato,Amélie Boichard,Huan-You Wang,Garrett M. Frampton,Scott M. Lippman,Caitlin F. Connelly,David Fabrizio,Vincent A. Miller,Jason K. Sicklick,Razelle Kurzrock +11 more
TL;DR: The results of this study suggest that PDL1 amplification occurs in a small subset of malignant tumors, even in the absence of microsatellite instability, high PD-L1 expression, and a high TMB.